European Neuropsychopharmacology最新文献

英文中文

Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-16 DOI: 10.1016/j.euroneuro.2025.03.009

Tanguy Taillefer de Laportalière , Mark Abie Horowitz , Thomas Soeiro , Marianne Lepetit , Adeline Jullien , Antoine Yrondi , Joanna Moncrieff , Florian Naudet , François Montastruc

引用次数: 0

Egr2 Modulation in the Medial Prefrontal Cortex Regulates Resistance to Stress-Induced Memory Impairments 内侧前额叶皮层中的 Egr2 调节作用可调节对压力诱发的记忆损伤的抵抗力

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-13 DOI: 10.1016/j.euroneuro.2025.03.010

Jung-Cheol Park , Hakyun Ryu , Nam-Heon Kim , Yong-Jae Jeon , Hyo Jung Kang , June-Seek Choi , ChiHye Chung , Jung-Soo Han

引用次数: 0

Exploring the prospective association of serum interleukin-1β and brain-derived neurotrophic factor with antidepressant treatment response

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-13 DOI: 10.1016/j.euroneuro.2025.03.004

Chan-Yeong Cho , Ji Hyeon Jeon , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Il-Seon Shin , Jae-Min Kim

This study investigated the prospective association of serum interleukin-1 beta (sIL-1β) and brain-derived neurotrophic factor (sBDNF) with 12-week antidepressant treatment outcomes in patients with depressive disorders. We analyzed baseline levels of sIL-1β and sBDNF in 1,086 patients participating in a naturalistic, stepwise antidepressant treatment study. Remission was defined by a Hamilton Depression Rating Scale score of ≤7 at 12 weeks. Logistic regression, adjusted for sociodemographic and clinical covariates, was used to assess the relationships between biomarker levels and treatment outcomes. Higher sIL-1β levels were significantly associated with non-remission at 12 weeks in patients with lower sBDNF levels, while in patients with higher sBDNF levels, sIL-1β did not significantly impact remission outcomes. The interaction between sIL-1β and sBDNF significantly associated with remission status, even after adjusting for confounders. The study suggests the significant role of the interplay between inflammatory and neuroplastic systems in influencing antidepressant treatment outcomes. These findings underscore the potential of integrating biomarker profiles to enhance personalized antidepressant strategies, advancing treatment precision in depressive disorders. Future research should focus on elucidating the dynamic mechanisms behind these biomarker interactions to further refine models that assess treatment responsiveness and develop targeted therapeutic interventions.

本研究调查了抑郁症患者血清白细胞介素-1β（sIL-1β）和脑源性神经营养因子（sBDNF）与 12 周抗抑郁治疗结果的前瞻性关联。我们分析了参加自然递进式抗抑郁治疗研究的 1086 名患者的 sIL-1β 和 sBDNF 基线水平。12周时汉密尔顿抑郁量表评分≤7分即为缓解。经社会人口学和临床协变量调整后，采用逻辑回归评估生物标志物水平与治疗结果之间的关系。在sBDNF水平较低的患者中，较高的sIL-1β水平与12周后未缓解显著相关，而在sBDNF水平较高的患者中，sIL-1β对缓解结果没有显著影响。即使在调整了混杂因素后，sIL-1β和sBDNF之间的相互作用仍与缓解状态有显著相关性。这项研究表明，炎症和神经可塑性系统之间的相互作用在影响抗抑郁治疗结果方面发挥着重要作用。这些发现强调了整合生物标志物特征以加强个性化抗抑郁策略的潜力，从而推进抑郁障碍的精准治疗。未来的研究应侧重于阐明这些生物标志物相互作用背后的动态机制，以进一步完善评估治疗反应性的模型，开发有针对性的治疗干预措施。

{"title":"Exploring the prospective association of serum interleukin-1β and brain-derived neurotrophic factor with antidepressant treatment response","authors":"Chan-Yeong Cho , Ji Hyeon Jeon , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Il-Seon Shin , Jae-Min Kim","doi":"10.1016/j.euroneuro.2025.03.004","DOIUrl":"10.1016/j.euroneuro.2025.03.004","url":null,"abstract":"<div><div>This study investigated the prospective association of serum interleukin-1 beta (sIL-1β) and brain-derived neurotrophic factor (sBDNF) with 12-week antidepressant treatment outcomes in patients with depressive disorders. We analyzed baseline levels of sIL-1β and sBDNF in 1,086 patients participating in a naturalistic, stepwise antidepressant treatment study. Remission was defined by a Hamilton Depression Rating Scale score of ≤7 at 12 weeks. Logistic regression, adjusted for sociodemographic and clinical covariates, was used to assess the relationships between biomarker levels and treatment outcomes. Higher sIL-1β levels were significantly associated with non-remission at 12 weeks in patients with lower sBDNF levels, while in patients with higher sBDNF levels, sIL-1β did not significantly impact remission outcomes. The interaction between sIL-1β and sBDNF significantly associated with remission status, even after adjusting for confounders. The study suggests the significant role of the interplay between inflammatory and neuroplastic systems in influencing antidepressant treatment outcomes. These findings underscore the potential of integrating biomarker profiles to enhance personalized antidepressant strategies, advancing treatment precision in depressive disorders. Future research should focus on elucidating the dynamic mechanisms behind these biomarker interactions to further refine models that assess treatment responsiveness and develop targeted therapeutic interventions.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 33-39"},"PeriodicalIF":6.1,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longitudinal brain age in first-episode mania youth treated with lithium or quetiapine

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-13 DOI: 10.1016/j.euroneuro.2025.03.013

Laura K.M. Han , Niousha Dehestani , Chao Suo , Rothanthi Daglas-Georgiou , Melissa Hasty , Linda Kader , Brendan P. Murphy , Christos Pantelis , Murat Yücel , Michael Berk , Lianne Schmaal

It is unclear if lithium and quetiapine have neuroprotective effects, especially in early stages of bipolar and schizoaffective disorders. Here, an age-related multivariate brain structural measure (i.e., brain-PAD) at baseline and changes in response to treatment after a first-episode mania (FEM) were examined. FEM participants were randomized to lithium (n=21) or quetiapine (n=18) monotherapy. T1-weighted scans were acquired at baseline, 3-months (FEM participants only) and 12-months. Brain age predictions for healthy controls (n=29) and young people with bipolar or schizoaffective disorder (15–25 years) were derived using a deep learning model trained on one of the largest datasets (N=53,542) to date. Notably, a higher brain-PAD value (predicted brain age - age) signifies an older-appearing brain. Baseline brain-PAD was higher in young people with FEM compared to controls (+1.70 year, p=0.04; Cohen's d=0.53 [SE=0.25], CI 95% [0.04 to 1.01]). However, no significant effects of time or treatment group, nor an interaction between the two, were observed throughout the course of the study. Baseline brain-PAD did not predict any change in symptomatic, quality of life or functional outcome scores over 12 months. In young individuals with FEM, baseline findings show their brains appeared older than controls. However, brain-PAD remained stable over time across treatment groups and neither baseline values nor treatment predicted 12-month outcomes. A longer follow-up with a larger sample is warranted to determine if treatment effects emerge later in bipolar and schizoaffective disorders.

Trial registration

Australian and New Zealand Clinical Trials Registry – ACTRN12607000639426.

{"title":"Longitudinal brain age in first-episode mania youth treated with lithium or quetiapine","authors":"Laura K.M. Han , Niousha Dehestani , Chao Suo , Rothanthi Daglas-Georgiou , Melissa Hasty , Linda Kader , Brendan P. Murphy , Christos Pantelis , Murat Yücel , Michael Berk , Lianne Schmaal","doi":"10.1016/j.euroneuro.2025.03.013","DOIUrl":"10.1016/j.euroneuro.2025.03.013","url":null,"abstract":"<div><div>It is unclear if lithium and quetiapine have neuroprotective effects, especially in early stages of bipolar and schizoaffective disorders. Here, an age-related multivariate brain structural measure (i.e., brain-PAD) at baseline and changes in response to treatment after a first-episode mania (FEM) were examined. FEM participants were randomized to lithium (n=21) or quetiapine (n=18) monotherapy. T1-weighted scans were acquired at baseline, 3-months (FEM participants only) and 12-months. Brain age predictions for healthy controls (n=29) and young people with bipolar or schizoaffective disorder (15–25 years) were derived using a deep learning model trained on one of the largest datasets (N=53,542) to date. Notably, a higher brain-PAD value (predicted brain age - age) signifies an older-appearing brain. Baseline brain-PAD was higher in young people with FEM compared to controls (+1.70 year, p=0.04; Cohen's d=0.53 [SE=0.25], CI 95% [0.04 to 1.01]). However, no significant effects of time or treatment group, nor an interaction between the two, were observed throughout the course of the study. Baseline brain-PAD did not predict any change in symptomatic, quality of life or functional outcome scores over 12 months. In young individuals with FEM, baseline findings show their brains appeared older than controls. However, brain-PAD remained stable over time across treatment groups and neither baseline values nor treatment predicted 12-month outcomes. A longer follow-up with a larger sample is warranted to determine if treatment effects emerge later in bipolar and schizoaffective disorders.</div></div><div><h3>Trial registration</h3><div>Australian and New Zealand Clinical Trials Registry – ACTRN12607000639426.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 40-48"},"PeriodicalIF":6.1,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-13 DOI: 10.1016/j.euroneuro.2025.03.007

Mark E. Schmidt , John A. Moyer , Iva Kezic , Xianhuang Zhou , Mahesh N. Samtani , Cathy Bleys , Shannon Dallas , Giacomo Salvadore , Wayne C. Drevets

The selective orexin-1 receptor antagonist JNJ-61393215 (tebideutorexant) has shown anti-panic properties in rodent and human panic-anxiety models. This double-blind, placebo-controlled, randomized, parallel-group, multicenter, phase 2a study evaluated the efficacy, safety, and tolerability of JNJ-61393215 in 222 patients (18–64 years) with major depressive disorder (MDD) with anxious distress who had experienced a suboptimal response to standard antidepressants. Eligible patients were randomized (1:1) to receive either adjunctive JNJ-61393215 (135 mg) or placebo, once daily. The primary objective was to evaluate the efficacy of JNJ-61393215 versus placebo, as assessed by the change from baseline to week 6 on the 17-item Hamilton Depression Rating Scale (HDRS₁₇). The key secondary objective was to evaluate the impact of JNJ-61393215 versus placebo on the severity of anxiety as measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) from baseline to week 6. The study results for the full intent-to-treat analysis dataset did not show significant treatment effects of adjunctive treatment with JNJ-61393215 on either the primary endpoint (the least squares mean difference [standard error]: −0.67 [0.893]; p=0.2227) or the key secondary endpoint (0.23 [1.007]; p=0.5889). The safety results were consistent with the known safety profile of JNJ-61393215 with no serious adverse events reported during the study. Overall, adjunctive treatment with an orexin-1 antagonist did not provide significant benefit relative to adjunctive placebo to patients with MDD and anxious distress.

Trial registration number: ClinicalTrials.gov Identifier: NCT04080752

{"title":"Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study","authors":"Mark E. Schmidt , John A. Moyer , Iva Kezic , Xianhuang Zhou , Mahesh N. Samtani , Cathy Bleys , Shannon Dallas , Giacomo Salvadore , Wayne C. Drevets","doi":"10.1016/j.euroneuro.2025.03.007","DOIUrl":"10.1016/j.euroneuro.2025.03.007","url":null,"abstract":"<div><div>The selective orexin-1 receptor antagonist JNJ-61393215 (tebideutorexant) has shown anti-panic properties in rodent and human panic-anxiety models. This double-blind, placebo-controlled, randomized, parallel-group, multicenter, phase 2a study evaluated the efficacy, safety, and tolerability of JNJ-61393215 in 222 patients (18–64 years) with major depressive disorder (MDD) with anxious distress who had experienced a suboptimal response to standard antidepressants. Eligible patients were randomized (1:1) to receive either adjunctive JNJ-61393215 (135 mg) or placebo, once daily. The primary objective was to evaluate the efficacy of JNJ-61393215 versus placebo, as assessed by the change from baseline to week 6 on the 17-item Hamilton Depression Rating Scale (HDRS<sub>17</sub>). The key secondary objective was to evaluate the impact of JNJ-61393215 versus placebo on the severity of anxiety as measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) from baseline to week 6<strong>.</strong> The study results for the full intent-to-treat analysis dataset did not show significant treatment effects of adjunctive treatment with JNJ-61393215 on either the primary endpoint (the least squares mean difference [standard error]: −0.67 [0.893]; p=0.2227) or the key secondary endpoint (0.23 [1.007]; p=0.5889). The safety results were consistent with the known safety profile of JNJ-61393215 with no serious adverse events reported during the study. Overall, adjunctive treatment with an orexin-1 antagonist did not provide significant benefit relative to adjunctive placebo to patients with MDD and anxious distress.</div><div><strong>Trial registration number:</strong> ClinicalTrials.gov Identifier: NCT04080752</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Supporting the call for clinical trials assessing physical exercise and creatine in depression: a response to “Muscle and the mind: The combination of creatine and exercise for depression?” 支持对抑郁症患者进行体育锻炼和肌酸临床试验评估的呼吁：对 "肌肉与心灵：肌酸与运动相结合治疗抑郁症？

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-13 DOI: 10.1016/j.euroneuro.2025.03.003

Nima Norbu Sherpa , Riccardo De Giorgi

引用次数: 0

Racial and ethnic diversity in zuranolone and brexanolone clinical trials for postpartum depression: A cross-sectional analysis of ClinicalTrials.gov

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-11 DOI: 10.1016/j.euroneuro.2025.03.005

Damian Swieczkowski , Aleksander Kwaśny , Michal Pruc , Lukasz Szarpak , Wiesław Jerzy Cubała

引用次数: 0

Creatine as a treatment for depression: A brain bioenergetics perspective

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-11 DOI: 10.1016/j.euroneuro.2025.03.014

Nicholas Fabiano , Brendon Stubbs

引用次数: 0

Predicting 10-year risk of chronic kidney disease in lithium-treated patients with bipolar disorder: A risk model development and internal cross-validation study

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-11 DOI: 10.1016/j.euroneuro.2025.03.008

Joe Kwun Nam Chan , Marco Solmi , Christoph U Correll , Corine Sau Man Wong , Heidi Ka Ying Lo , Francisco Tsz Tsun Lai , Wing Chung Chang

Lithium is a first-line maintenance treatment for bipolar-disorder (BD) but has increased risk for chronic-kidney-disease (CKD). There is a paucity of research on risk-model development predicting CKD during/following lithium treatment, and none was conducted in Asian regions. This study aimed to derive and validate 10-year risk prediction model for CKD-stage 3 in first-diagnosed BD patients receiving ≥ 1 prescription of lithium during 2002–2018 in Hong-Kong, using electronic-medical-record database of public-healthcare services. Literature-informed predictor selection included demographics, physical comorbidities, mean lithium serum-levels and non-lithium psychotropic use. The risk-equation was developed using Least-Absolute-Shrinkage-and-Selection-Operator (LASSO) Cox-proportional hazards regression model with 4-fold internal cross-validation over 1,000 iterations. We identified 2,258 lithium-treated BD patients, with CKD incidence of 12.6 per 1000 person-years (95 %CI=11.1–14.4) over a median follow-up of 7.7 years (interquartile range=3.7–12.3). Our results showed that older age at BD-diagnosis, male sex, physical comorbidities, higher mean lithium serum-level, fewer antipsychotic and mood-stabilizing anticonvulsant use, and greater antidepressant exposure were independent risk factors predicting CKD, with an event-per-variable ratio of 25.2. The 10-year risk prediction model had satisfactory area-under-the-curve (AUC) (0.74 [95 %CI=0.66–0.83]), with good calibration (calibration slope=0.88 [95 %CI=0.61–1.15]; observed/expected risk ratio=1.14 [95 %CI=0.86–1.42]), and discrimination performances (Harrell's C-index=0.75 [95 %CI=0.68–0.82]; Royston and Sauerbrei's D statistic=1.45 [95 %CI=0.99–1.92]). In conclusion, this CKD risk-model for lithium-treated BD patients demonstrated satisfactory prediction performance in a predominantly-Chinese population. Further research including external validation is needed to verify model performance to facilitate implementation of this CKD risk prediction tool for individualized clinical decision-making and outcomes in real-world practice.

锂是双相情感障碍（BD）的一线维持治疗药物，但会增加慢性肾脏疾病（CKD）的风险。关于锂治疗期间/治疗后预测慢性肾脏病的风险模型开发的研究很少，而且没有一项研究是在亚洲地区进行的。本研究旨在利用公共医疗保健服务的电子病历数据库，对2002-2018年期间在香港接受过≥1次锂处方治疗的初诊BD患者进行10年CKD第3期风险预测模型的推导和验证。根据文献资料选择的预测因子包括人口统计学特征、身体合并症、平均锂血清水平和非锂类精神药物的使用。风险方程采用最小绝对值-收缩-选择操作器（LASSO）Cox比例危害回归模型，并经过1000次迭代的4倍内部交叉验证。我们确定了 2,258 名接受过锂治疗的 BD 患者，在 7.7 年（四分位间范围=3.7-12.3）的中位随访期间，CKD 发病率为每 1000 人年 12.6 例（95 %CI=11.1-14.4）。我们的研究结果表明，BD 诊断年龄较大、男性、身体合并症、平均锂血清水平较高、较少使用抗精神病药和稳定情绪抗惊厥药、较多抗抑郁药暴露是预测 CKD 的独立风险因素，事件与变量的比值为 25.2。10 年风险预测模型的曲线下面积（AUC）（0.74 [95 %CI=0.66-0.83] ）令人满意，校准效果良好（校准斜率=0.88 [95 %CI=0.61-1.15]；观察/预期风险比=1.14 [95 %CI=0.86-1.42] ），并且具有良好的区分性能（Harrell 的 C 指数=0.75 [95 %CI=0.68-0.82] ；Royston 和 Sauerbrei 的 D 统计量=1.45 [95 %CI=0.99-1.92] ）。总之，这一针对锂治疗 BD 患者的 CKD 风险模型在以中国人为主的人群中表现出了令人满意的预测性能。还需要进一步的研究，包括外部验证，以验证模型的性能，从而促进这一CKD风险预测工具在实际临床实践中用于个体化临床决策和结果。

{"title":"Predicting 10-year risk of chronic kidney disease in lithium-treated patients with bipolar disorder: A risk model development and internal cross-validation study","authors":"Joe Kwun Nam Chan , Marco Solmi , Christoph U Correll , Corine Sau Man Wong , Heidi Ka Ying Lo , Francisco Tsz Tsun Lai , Wing Chung Chang","doi":"10.1016/j.euroneuro.2025.03.008","DOIUrl":"10.1016/j.euroneuro.2025.03.008","url":null,"abstract":"<div><div>Lithium is a first-line maintenance treatment for bipolar-disorder (BD) but has increased risk for chronic-kidney-disease (CKD). There is a paucity of research on risk-model development predicting CKD during/following lithium treatment, and none was conducted in Asian regions. This study aimed to derive and validate 10-year risk prediction model for CKD-stage 3 in first-diagnosed BD patients receiving ≥ 1 prescription of lithium during 2002–2018 in Hong-Kong, using electronic-medical-record database of public-healthcare services. Literature-informed predictor selection included demographics, physical comorbidities, mean lithium serum-levels and non-lithium psychotropic use. The risk-equation was developed using Least-Absolute-Shrinkage-and-Selection-Operator (LASSO) Cox-proportional hazards regression model with 4-fold internal cross-validation over 1,000 iterations. We identified 2,258 lithium-treated BD patients, with CKD incidence of 12.6 per 1000 person-years (95 %CI=11.1–14.4) over a median follow-up of 7.7 years (interquartile range=3.7–12.3). Our results showed that older age at BD-diagnosis, male sex, physical comorbidities, higher mean lithium serum-level, fewer antipsychotic and mood-stabilizing anticonvulsant use, and greater antidepressant exposure were independent risk factors predicting CKD, with an event-per-variable ratio of 25.2. The 10-year risk prediction model had satisfactory area-under-the-curve (AUC) (0.74 [95 %CI=0.66–0.83]), with good calibration (calibration slope=0.88 [95 %CI=0.61–1.15]; observed/expected risk ratio=1.14 [95 %CI=0.86–1.42]), and discrimination performances (Harrell's C-index=0.75 [95 %CI=0.68–0.82]; Royston and Sauerbrei's D statistic=1.45 [95 %CI=0.99–1.92]). In conclusion, this CKD risk-model for lithium-treated BD patients demonstrated satisfactory prediction performance in a predominantly-Chinese population. Further research including external validation is needed to verify model performance to facilitate implementation of this CKD risk prediction tool for individualized clinical decision-making and outcomes in real-world practice.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 24-30"},"PeriodicalIF":6.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143817494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on the Article “Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality” 关于 "利用虚拟现实技术优化鉴别诊断并确定跨诊断治疗目标 "一文的评论

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology

Pub Date : 2025-04-11 DOI: 10.1016/j.euroneuro.2025.02.016

Sijia Liu , Xicai Liang , Juntong Liu

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Neuropsychopharmacology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀